Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., . . . Laville, M. (2013). Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. American Diabetes Association.
Chicago-stil citatCariou, Bertrand, et al. Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. American Diabetes Association, 2013.
MLA-referensCariou, Bertrand, et al. Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects. American Diabetes Association, 2013.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.